HC Wainwright reiterated their buy rating on shares of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) in a report released on Friday morning. HC Wainwright currently has a $21.00 price target on the biotechnology company’s stock.

Several other brokerages also recently commented on CNCE. BidaskClub downgraded shares of Concert Pharmaceuticals from a hold rating to a sell rating in a report on Friday, August 4th. Zacks Investment Research raised shares of Concert Pharmaceuticals from a sell rating to a hold rating in a report on Thursday, August 10th. ValuEngine raised shares of Concert Pharmaceuticals from a sell rating to a hold rating in a report on Friday, September 1st. Stifel Nicolaus reaffirmed a buy rating and set a $30.00 target price on shares of Concert Pharmaceuticals in a report on Sunday, October 22nd. Finally, Mizuho began coverage on shares of Concert Pharmaceuticals in a report on Thursday, October 26th. They set a buy rating and a $23.00 target price for the company. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. Concert Pharmaceuticals presently has a consensus rating of Hold and a consensus price target of $23.00.

Shares of Concert Pharmaceuticals (NASDAQ:CNCE) traded up $1.07 on Friday, hitting $17.53. 279,500 shares of the stock were exchanged, compared to its average volume of 233,585. Concert Pharmaceuticals has a 52 week low of $7.11 and a 52 week high of $19.11.

ILLEGAL ACTIVITY WARNING: “Concert Pharmaceuticals, Inc. (CNCE) Receives Buy Rating from HC Wainwright” was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another domain, it was copied illegally and republished in violation of international copyright & trademark laws. The correct version of this article can be read at https://www.watchlistnews.com/concert-pharmaceuticals-inc-cnce-receives-buy-rating-from-hc-wainwright/1701038.html.

In other Concert Pharmaceuticals news, insider Value Fund L. P. Biotechnology acquired 331,916 shares of the business’s stock in a transaction on Thursday, October 19th. The stock was purchased at an average price of $15.84 per share, with a total value of $5,257,549.44. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Ryan Lynch sold 3,500 shares of the business’s stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $14.51, for a total transaction of $50,785.00. Following the completion of the sale, the insider now directly owns 9,500 shares of the company’s stock, valued at approximately $137,845. The disclosure for this sale can be found here. Insiders own 10.10% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. The Manufacturers Life Insurance Company boosted its holdings in Concert Pharmaceuticals by 1.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,052 shares of the biotechnology company’s stock valued at $210,000 after purchasing an additional 287 shares during the period. American International Group Inc. boosted its holdings in Concert Pharmaceuticals by 7.1% in the 1st quarter. American International Group Inc. now owns 10,156 shares of the biotechnology company’s stock valued at $173,000 after purchasing an additional 677 shares during the period. Geode Capital Management LLC raised its position in shares of Concert Pharmaceuticals by 0.6% in the 1st quarter. Geode Capital Management LLC now owns 142,740 shares of the biotechnology company’s stock valued at $2,435,000 after buying an additional 838 shares in the last quarter. Alps Advisors Inc. raised its position in shares of Concert Pharmaceuticals by 6.3% in the 2nd quarter. Alps Advisors Inc. now owns 20,362 shares of the biotechnology company’s stock valued at $284,000 after buying an additional 1,200 shares in the last quarter. Finally, Rhumbline Advisers raised its position in shares of Concert Pharmaceuticals by 8.0% in the 2nd quarter. Rhumbline Advisers now owns 20,253 shares of the biotechnology company’s stock valued at $283,000 after buying an additional 1,500 shares in the last quarter. 62.51% of the stock is owned by hedge funds and other institutional investors.

About Concert Pharmaceuticals

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.

Receive News & Ratings for Concert Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.